Home

Insights

Bliss GVS Pharma Ltd P/E Ratio

Bliss GVS Pharma Ltd P/E Ratio

download
stocks purchased

₹ 0.4 Cr

Volume transacted

stocks purchased

34.1 K

stocks traded

Image

Bliss GVS Pharma Ltd

NSE: BLISSGVS

PE

11.9

Last updated : 17 May 15:30 pm

Key Highlights

    The P/E Ratio of Bliss GVS Pharma Ltd is 11.9 as of 17 May 15:30 pm .a1#The P/E Ratio of Bliss GVS Pharma Ltd changed from 15 on March 2019 to 10.5 on March 2023 . This represents a CAGR of -6.89% over 5 years. a1#The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 109.55 as of 17 May 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.7 to 27.7 in 5 years. This represents a CAGR of -0.71%a1# The PE Ratio of Automobile industry is 27.2. The PE Ratio of Finance industry is 13.6. The PE Ratio of IT - Software industry is 27.9. The PE Ratio of Pharmaceuticals industry is 27.7. The PE Ratio of Retail industry is 94.8. The PE Ratio of Textiles industry is 21.1. In 2023a1#The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1856 crore on March 2019 to ₹ 742.09 crore on March 2023 . This represents a CAGR of -16.75% over 5 years. a1#The Revenue of Bliss GVS Pharma Ltd changed from ₹ 195.67 crore to ₹ 203.73 crore over 8 quarters. This represents a CAGR of 2.04% a1#The EBITDA of Bliss GVS Pharma Ltd changed from ₹ 45.86 crore to ₹ 4.75 crore over 8 quarters. This represents a CAGR of -67.82% a1#The Net Profit of Bliss GVS Pharma Ltd changed from ₹ 27.48 crore to ₹ -4.91 crore over 8 quarters. This represents a CAGR of NaN% a1#The Dividend Payout of Bliss GVS Pharma Ltd changed from 13.85 % on March 2019 to 6.09 % on March 2023 . This represents a CAGR of -15.15% over 5 years. a1#

Open Demat Account

Lead form image

+91

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

*By signing up you agree to our terms & conditions

×

P/E Ratio Over Time

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

P/E Ratio Over Time

Period
Mar '1915
Mar '2010.7
Mar '2114.9
Mar '2253.1
Mar '2310.5

Fundamental Metrics

Market Cap

1,146 Cr

EPS

9.1

P/E Ratio (TTM) *

11.9

P/B Ratio (TTM) *

1.2

Day’s High

110.5

Day’s Low

108.75

DTE *

0.1

ROE *

9.9

52 Week High

148.95

52 Week Low

71.0

ROCE *

14.3

* All values are consolidated

* All values are consolidated

Image

Bliss GVS Pharma Ltd

NSE: BLISSGVS

PRICE

109.55

0.40(0.37%)

stock direction

Last updated : 17 May 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Bliss GVS Pharma Ltd

Strength

1

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

Asset Value vs Market Value

Market Value

1,143

Asset Value

714

0.6 X

Value addition

* All values are in Rupees

PE Ratio Over Market Cap

Key Valuation Metric

Earnings

75 Cr

11.9 X

PE Ratio

Market Cap

₹1142Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio

PS Ratio

PB Ratio

Earnings

75 Cr

11.9 X

PE Ratio

Market Cap

₹1142Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Bliss GVS Pharma Ltd PE Ratio Calculation

  • The Price-to-Earnings (PE) ratio, also known as the P/E Ratio, is a fundamental financial metric used to assess the valuation of a company's stock in relation to its earnings performance. For Bliss GVS Pharma Ltd, the PE Ratio is calculated as follows:

P/E Ratio

=

Market Capitalization

Net Income

  • Given the current market conditions, Bliss GVS Pharma Ltd's Share Price stands at 109.55. The Earnings per Share (Diluted) for the trailing twelve months (TTM) ending in 2024-05-17T00:00:00 is 9.15. Substituting the values into the formula, PE Ratio becomes as follows: PE Ratio = 109.55/ 9.15= 11.93.

P/E Ratio

=

Stock Price

Earning Per Share

  • This indicates that Bliss GVS Pharma Ltd's stock is trading at approximately 11.93 times its earnings per share for the trailing twelve months. Alternatively, the PE Ratio can also be computed using the company's overall financial performance: PE Ratio = Market Cap / Net Income. Where Market Cap represents the total market capitalization of the company, and Net Income signifies the total earnings after expenses and taxes.

Understanding Bliss GVS Pharma Ltd’s PE Ratio (BSE: BLISSGVS)

    The Price-to-Earnings (PE) ratio, used to assess Bliss GVS Pharma Ltd's stock (BSE: BLISSGVS), indicates how many years it would take for the company to earn back the stock price. If a company earns ₹2 per share annually and its stock trades at ₹30, the PE ratio is 15, signifying a 15-year payback period assuming steady earnings. Earnings fluctuate, affecting the payback period, Growing earnings shorten the recovery time while declining earnings extend it. Shareholders favor shorter payback periods, preferring lower PE stocks. Among stocks with the same PE ratio, faster-growing businesses are preferred. A company with losses makes the PE ratio meaningless. Peter Lynch introduced the PEG ratio to compare stocks with different growth rates, dividing the PE ratio by the growth rate. A company is considered fairly valued when its PE ratio matches its growth rate. The PE ratio, applicable across industries, measures stock valuation based on earnings power. It indicates how quickly an investment can be recouped. Unlike the PB ratio, which assesses valuation based on the balance sheet, the PE ratio focuses on earnings. Overall, the PE ratio provides insights into stock valuation, aligning with investors' preference for faster returns.

×

Market Cap Over Time

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Market Cap Over Time

Period
Mar '191856
Mar '201040
Mar '211018
Mar '22798
Mar '23742

* All values are a in crore

×

Revenue Over Time

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Revenue Over Time

Period
Jun '22196
Sep '22175
Dec '22211
Mar '22188
Jun '23165
Sep '23224
Dec '23206
Mar '23204

* All values are a in crore

×

EBITDA Over Time

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

EBITDA Over Time

Period
Jun '2246
Sep '2227
Dec '2253
Mar '229
Jun '2329
Sep '2367
Dec '2349
Mar '235

* All values are a in crore

×

Net Profit Over Time

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Net Profit Over Time

Period
Jun '2227
Sep '2216
Dec '2230
Mar '223
Jun '2314
Sep '2343
Dec '2329
Mar '23-5

* All values are a in crore

×

Dividend Payout Over Time

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Dividend Payout Over Time

Period
Mar '1914
Mar '206
Mar '218
Mar '226
Mar '236

* All values are a in %

About Bliss GVS Pharma Ltd

About Bliss GVS Pharma Ltd

    Bliss GVS Pharma Ltd is an export-oriented pharmaceutical company. It is among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. Bliss GVS Pharma has presence in antimalarial, antifungal, antibacterial, anti-inflammatory and antibiotic therapeutic segments. It is a leading player in the antimalarial branded formulations segment. Bliss GVS Pharma is the only EU-GMP certified suppositories manufacturer in India. The company has a dedicated the R&D Centre for development of Suppositories, Semi Solids and Oral Solids with an experienced Team of over 50 Scientists for formulation development and analytical method development and certified by the Department of Scientific & Industrial Research (DSIR), Government of India. Incorporated in 1984 as a private limited company under the name Bliss Chemicals & Pharmaceuticals India Ltd, the company commenced its business in 1985. In 1994 the company introduced a new pharmaceutical product VAGID.During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR). During the year under review, the company invested in 51% share capital of Lifeon Labs Pvt Ltd. During the year under review, Bliss GVS Pharma faced challenges in Ghana, where delays in registration resulted in adverse regulatory action. However, the company took quick, corrective measures to resolve these issues. The business is now backing on track in Ghana. During the year ended 31 March 2015, Bliss GVS Pharma formed a new company Asterisk Lifesciences Limited as a wholly owned foreign subsidiary in United Kingdom for the purpose of facilitating registrations and marketing of pharmaceutical formulations in the European continent. During the financial year ended 31 March 2016, Bliss GVS Pharma continued to grow in various geographies in Kenya, Nigeria and France. Such growth was mainly achieved due to contract manufacturing and consistent focus on new product launch in Kenya and Nigeria. Bliss GVS Pharma continued to strengthen its operations and creation of robust Quality Manufacturing operations during the year ended 31 March 2017, The company's investment in managed healthcare services delivered encouraging results with the company procuring USD 111.40 mMillion contract from Aon. This presents a great platform for the unit to build on its recent success to successfully bid for other such contracts. During the year ended 31 March 2018, Bliss GVS Pharma divested three subsidiaries viz. Lifeon Labs Private Limited, Bliss Indasi Lifescience Private Limited and Shree Salespack Private Limited and one materially significant step down subsidiary Bliss GVS Healthcare Limited, Nairobi to focus on its core pharmaceutical operations, which have been a steady source of growth. As on 31 March 2019,the company has one domestic and 3 overseas subsidiaries. During the FY2020,the Company has completed the commissioning & qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company in terms of planned production capacity when completed. It is equipped with state-of-the-art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention. The unit is spread on an overall area of about 200,000 sq. ft. and is intended to further augment the production capacities for the Company. The Company has 4 wholly owned subsidiaries and 3 step-down subsidiaries as on 31 March 2020. During the year, ECO Rich Cosmetics India Private Limited discontinued or ceased to be a step-down subsidiary of the Company consequent to loss of control. The Company's wholly owned subsidiary Bliss GVS Clinic HealthCare Pte. Ltd. situated at Singapore became a material subsidiary for the Company during the financial year 2019-2020.

Bliss GVS Pharma Ltd News Hub

News

Bliss GVS Pharma to convene AGM

Bliss GVS Pharma announced that the 39th Annual General Meeting(AGM) of the company will b...

Read more

04 May 2024 16:04

News

Board of Bliss GVS Pharma recommends final dividend

Bliss GVS Pharma announced that the Board of Directors of the Company at its meeting held ...

Read more

03 May 2024 10:36

News

Bliss GVS Pharma announces board meeting date

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 2 May 202...

Read more

26 Apr 2024 11:02

News

Bliss GVS Pharma to discuss results

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 23 Januar...

Read more

17 Jan 2024 11:25

News

Bliss GVS Pharma to discuss results

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 1 Novembe...

Read more

26 Oct 2023 15:28

News

Bliss GVS Pharma schedules board meeting

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 1 August ...

Read more

25 Jul 2023 12:23

Product Composition by Percentage (Revenue)

FAQs for PE of Bliss GVS Pharma Ltd

What is Bliss GVS Pharma Ltd current share price?

The current market price of Bliss GVS Pharma Ltd as of May 17, 2024 is ₹109.55.

What is Bliss GVS Pharma Ltd's market cap?

Bliss GVS Pharma Ltd's market capitalisation stood at ₹1,142 Cr as of May 17, 2024

What are Bliss GVS Pharma Ltd's total net assets?

According to Bliss GVS Pharma Ltd's most recent financial filings, the company's net assets total ₹714.4 Cr.

Is Bliss GVS Pharma Ltd making a profit or loss?

Bliss GVS Pharma Ltd's net Profit as of May 17, 2024 is close to ₹75 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199